Cargando…
A phase 1 first‐in‐human study of GS‐0189, an anti‐signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non‐Hodgkin lymphoma (NHL)
Signal regulatory protein alpha (SIRPα) is the receptor for cluster of differentiation (CD)47, a potent “don't eat me” signal for macrophages. Disruption of CD47‐SIRPα signaling in the presence of prophagocytic signals can lead to enhanced phagocytosis of tumor cells, resulting in a direct anti...
Autores principales: | Narkhede, Mayur, Bartlett, Nancy L., Ibrahimi, Sami, Popplewell, Leslie, Seto, Anna, Bates, Jamie, Lee, Yeonju, Ganti, Vaishnavi, Han, Ling, Chen, Tianling, Patel, Manish R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188468/ https://www.ncbi.nlm.nih.gov/pubmed/37206279 http://dx.doi.org/10.1002/jha2.687 |
Ejemplares similares
-
A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials
por: Kostakoglu, Lale, et al.
Publicado: (2023) -
Plasma thymus and activation‐regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma
por: Zijtregtop, Eline A. M., et al.
Publicado: (2020) -
Real‐world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000–2014, focusing on patients aged >60 years
por: Wahlin, Björn Engelbrekt, et al.
Publicado: (2021) -
Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020) -
First‐line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes
por: Avigdor, Abraham, et al.
Publicado: (2022)